Feasibility Study to Assess Canagliflozin Distribution and Sodium‐Glucose Co‐Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit with a large interindividual variation. The underlying mechanisms for this variation in response might be attributed...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2023-06, Vol.113 (6), p.1295-1303
Hauptverfasser:	Hoek, Sjoukje, Willemsen, Antoon T. M., Visser, Ton, Heeres, Andre, Mulder, Douwe J., Bokkers, Reinoud P. H., Slart, Riemer H. J. A., Elsinga, Philip H., Heerspink, Hiddo J. L., Stevens, Jasper
Format:	Artikel
Sprache:	eng
Schlagworte:	Canagliflozin - pharmacology Canagliflozin - therapeutic use Diabetes Mellitus, Type 2 - diagnostic imaging Diabetes Mellitus, Type 2 - drug therapy Feasibility Studies Glucose - metabolism Glucose - therapeutic use Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Kinetics Sodium - metabolism Sodium - therapeutic use Sodium-Glucose Transporter 2 Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!